March 14, 2018 / 12:15 PM / 3 months ago

BRIEF-FDA Acceptance Of IND For Tyme To Begin Phase II Trial In Pancreatic Cancer

March 14 (Reuters) - Tyme Technologies Inc:

* FDA ACCEPTANCE OF IND FOR TYME TO BEGIN PHASE II TRIAL IN PANCREATIC CANCER

* TYME TECHNOLOGIES INC - EXPECTS INITIAL CLINICAL SITES TO BEGIN ENROLLING PATIENTS OVER NEXT FEW WEEKS IN PHASE II TRIAL

* TYME TECHNOLOGIES INC - ‍ FINAL DATA FROM AN ONGOING PHASE II CLINICAL TRIAL EVALUATING SM-88 FOR PROSTATE CANCER EXPECTED AROUND YEAR-END 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below